Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

CHTP - Chelsea Therapeutics International

790 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 ... 36 37 38 39 40 » | Laatste

Omlaag ↓

ludwig mack 18 november 2011 17:45

Chelsea Therapeutics (CHTP) is trading around $4.56. CHTP is a biotechnology company, based in North Carolina. These shares have traded in a range between $3.25 to $8.20 in the last 52 weeks. The 50-day moving average is $4.34 and the 200-day moving average is $4.44. Chelsea is pursuing an orphan drug strategy for a drug called Northera (Droxidopa) which is for the treatment of hypotension. (Yes, that's Hypotension, not hypertension.) This treatment has been approved and marketed in Japan for over 15 years, and generates about $50 million in revenue in that country. Recently, Chelsea released positive data on this drug and it caused an analyst to raise the price target to $18 due to their belief this will be approved early in 2012, see that here. I believe Chelsea is a low risk, high potential biotech stock. The new drug application for Northera could be approved in the first quarter of 2012. That is not long to wait for what could be exceptional gains.

seekingalpha.com/article/308915-biote...

junkbond 29 november 2011 07:09

Dikke insider buy van de Chief Medical Officer. Dik 45k op 4.46

ludwig mack 29 november 2011 14:38

Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference

CHARLOTTE, N.C., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET on November 30, 2011 at New York Palace Hotel.

Dr. Simon Pedder, Chelsea's Chief Executive Officer, will provide a brief overview of the company's product pipeline, clinical development status, as well as the FDA's recent acceptance for filing and designation of priority review of its new drug application (NDA) for NORTHERA™ for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Pedder's presentation will be webcast live and archived for 90 days on Chelsea's website, www.chelseatherapeutics.com.

svenhedin 29 november 2011 16:17

Chelsea Therapeutics International, Ltd. (CHTP) is a biotechnology company developing a variety of potential treatments including Northera (TM) ("Droxidopa"), which is for the treatment of hypotension as well as two clinical stage product candidates for immunological disorders, CH-1504 and CH-4051. Chelsea could receive marketing approval for Northera in the first quarter of 2012 and this would lead to the possible commercialization of Northera in the second quarter of 2012. We believe the chances for approval are very high because Northera ("Droxidopa") is currently approved and marketed in Japan for the treatment of orthostatic hypotension. This company has a solid balance sheet with about $57 million in cash. We view Chelsea as a low risk biotech stock with the potential to double or triple from current levels. In addition, the technicals are starting to look good and the stock could soon be poised for a major rally.

Catalysts: Marketing approval for Northera (TM) from the FDA in the first quarter of 2012.
52 week range: $3.25 to $8.20
12 Month Target Price: $11 Long-Term Target Price: $16

www.rallyresearch.com/Biotech_Health_...

ludwig mack 29 november 2011 21:36

Chelsea Therapeutics Internatio
(NasdaqCM: CHTP )

Real Time 4.83 Up 0.24 (5.23%) 3:27PM EST
Last Trade: 4.8499
Trade Time: 3:20PM EST
Change: Up 0.2599 (5.66%)
Prev Close: 4.59
Open: 4.68
Bid: 4.84 x 400
Ask: 4.85 x 1800
1y Target Est: 11.33
Day's Range: 4.55 - 4.85
52wk Range: 3.25 - 8.20
Volume: 362,365
Avg Vol (3m): 337,684
Market Cap: 299.95M
P/E (ttm): N/A
EPS (ttm): -0.89
Div & Yield: N/A (N/A)

volume is mooi.
gr

ludwig mack 30 november 2011 16:01

Last Trade: 5.05
Trade Time: 9:44AM EST
Change: Up 0.17 (3.48%)
Prev Close: 4.88
Open: 4.96
Bid: 5.03 x 800
Ask: 5.04 x 200
1y Target Est: 11.33
Day's Range: 4.94 - 5.0770
52wk Range: 3.25 - 8.20
Volume: 66,326
Avg Vol (3m): 337,584
Market Cap: 312.33M
P/E (ttm): N/A
EPS (ttm): -0.89
Div & Yield: N/A (N/A)

net open en al best volume en mooie prijs

[verwijderd] 30 november 2011 22:24

Na lang wachten begint de potentie eindelijk een beetje zichtbaar te worden. Naar mijn inschatting nog niet meer dan een aanloopje naar vééééél meer!!

svenhedin 2 december 2011 15:25

Wie kan uit dit bericht een verstandige konklusie trekken en melden ?

CHTP
Chelsea Therapeutics International, Ltd.
NASDAQ-CM Volatility seller sets sights on Chelsea
12/2/2011 3:44:18 AM - optionMONSTER

Read more: www.nasdaq.com/aspxcontent/newsheadli...

[verwijderd] 2 december 2011 16:48

Ach, een jongetje, dat graag zijn succes wereldkundig maakt. Hij loopt het risico, in januari a.s. 200.000 aandelen geleverd te krijgen op $ 5.-- als ze lager zijn. Zijn ze hoger, dan is zijn ontvangen bedrag van $ 120.000.- pure winst.

svenhedin 2 december 2011 19:26

Hier nog een uitleg:

Re: Volatility Seller Story 2-Dec-11 12:15 pm

The trader has sold put options at $5 with the
anticipation that the stock will not go below
that price. If it stays above or at $5 by the third
Friday of Jan 12, he pockets the premium. This has
no effect on CHTP pps although it is a positive bet
on CHTP's ability to stay above $5.

svenhedin 2 december 2011 19:30

De laatste link werkt met Search: CHTP

Droxidopa/Carbidopa for Fibromyalgia 2-Dec-11 10:51 am Since data from the Phase II Droxidopa/Carbidopa trial is likely the next news impacting CHTP, here are a few links that relate to Drox/Carbidopa for Fibro:

Link to initial trial approval in UK that describes (in layman's terms) what they hope to accomplish:

www.fibroaction.org/News/Droxidop...

Link to the trial at ClinicalTrials.gov (note 11/14 completion):

clinicaltrials.gov/ct2/show/NCT01...

Link to report from Data Monitoring Committee issuing go ahead for trial, focusing on 7 drox/carb combination arms (7/7/2011):

www.91outcomes.com/2010/07/fibrom...!...

Link to issuance of patent for Drox alone or in combination for treatment of Fibro (9/6/2011):

www.marketwatch.com/story/chelsea...

That brings us to where we sit today, awaiting hopefully positive results for the Droxidopa/Carbidopa combination therapy arms of the study by YE 2011.

ludwig mack 2 december 2011 21:56

quote:
svenhedin schreef op 2 december 2011 19:30:
De laatste link werkt met Search: CHTP

Droxidopa/Carbidopa for Fibromyalgia 2-Dec-11 10:51 am Since data from the Phase II Droxidopa/Carbidopa trial is likely the next news impacting CHTP, here are a few links that relate to Drox/Carbidopa for Fibro:

Link to initial trial approval in UK that describes (in layman's terms) what they hope to accomplish:

www.fibroaction.org/News/Droxidop...

Link to the trial at ClinicalTrials.gov (note 11/14 completion):

clinicaltrials.gov/ct2/show/NCT01...

Link to report from Data Monitoring Committee issuing go ahead for trial, focusing on 7 drox/carb combination arms (7/7/2011):

www.91outcomes.com/2010/07/fibrom...!...

Link to issuance of patent for Drox alone or in combination for treatment of Fibro (9/6/2011):

www.marketwatch.com/story/chelsea...

That brings us to where we sit today, awaiting hopefully positive results for the Droxidopa/Carbidopa combination therapy arms of the study by YE 2011.

eerste twee en de laatste werken niet meer.
ok, gr

ludwig mack 2 december 2011 21:57

overweeg om nog bij te kopen, maar aarzel;
nu gewoon is afwachten wat er gebeurt en niet de zenuwen .....
wat ik van de zomer bij daling verkocht niet meer teruggekocht.
gr

ludwig mack 2 december 2011 22:02

quote:
oudje schreef op 2 december 2011 16:48:
Ach, een jongetje, dat graag zijn succes wereldkundig maakt. Hij loopt het risico, in januari a.s. 200.000 aandelen geleverd te krijgen op $ 5.-- als ze lager zijn. Zijn ze hoger, dan is zijn ontvangen bedrag van $ 120.000.- pure winst.

en wanneer nieuws?
eerst kwartaal, dus in ieder geval na vervaldatum put.
gr

junkbond 3 december 2011 09:28

Volgens CHTP deze maand ..Results Droxidopa Phase II Fibromyalgia

junkbond 5 december 2011 08:30

6 Undervalued Stocks With New Insider Buying.

Chelsea Therapeutics (CHTP) is trading around $5.45. Chelsea is a biotechnology company, based in North Carolina. These shares have traded in a range between $3.25 to $8.20 in the last 52 weeks. The 50-day moving average is $4.41 and the 200-day moving average is $4.43. Chelsea is pursuing an orphan drug strategy for a drug called Northera (Droxidopa) which is for the treatment of hypotension. (Yes, that's Hypotension, not hypertension.) This treatment has been approved and marketed in Japan for over 15 years, and generates about $50 million in revenue in that country. The new drug application for Northera could be approved in the first quarter of 2012. That is not long to wait for what could be exceptional gains in this low risk, high potential biotech. This is one of my favorite biotechs, and the chart looks great now too. A director recently bought 45,141. seekingalpha.com/article/311743-6-und...

[verwijderd] 5 december 2011 19:43

Vrijdag 25/11 gesloten op $ 4.35

Vandaag de zesde achtereenvolgende stijging?

Koers nu $ 5.74, een plus van bijna 32%.

Denken we straks in februari/maart, dat dit nog slechts een beginnetje is?

ludwig mack 6 december 2011 18:14

paar bedrijven met afwachting goedkeuring, inclusief chesea:

seekingalpha.com/article/311872-5-hig...

ludwig mack 13 december 2011 17:12

seekingalpha.com/article/313179-9-bio...

[verwijderd] 13 december 2011 22:43

Gisteren 3 centjes winst + waardedaling euro;
Vandaag 5 cent verlies, ruimschoots gecompenseerd door de winnende dollar.
Kortom: goed resultaat in twee nogal wankele dagen.

Seeking Alpha blijft aardig bezig!

790 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 ... 36 37 38 39 40 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX	918,72	-5,89	-0,64%	14 jun
AMX	878,45	-16,03	-1,79%	14 jun
ASCX	1.218,76	-18,67	-1,51%	14 jun
BEL 20	3.833,37	-35,40	-0,92%	14 jun
Germany40^	18.004,30	+2,28	+0,01%	14 jun
US30^	38.584,80	0,00	0,00%	14 jun
US500^	5.432,55	0,00	0,00%	14 jun
Nasd100^	19.665,00	0,00	0,00%	14 jun
Japan225^	38.512,90	0,00	0,00%	14 jun
WTI	78,03	0,00	0,00%	14 jun
Brent	82,52	0,00	0,00%	14 jun
EUR/USD	1,0704	-0,0002	-0,02%	01:30
BTC/USD	66.596,97	-333,57	-0,50%	01:29
Gold spot	2.327,96	-4,73	-0,20%	01:30